Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Low-dose Darunavir in a Switch Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is aged ≥18 years~* Participant weight \>40kg~* Participant is on a LPV/r-containing regimen for at least 6 months with no history of other protease inhibitors~* Participant has a plasma HIV-1 RNA level \<50 copies/mL in the last 60 days~* Participant is informed and has the ability to comprehend the full nature and purpose of the study, and give voluntary written informed consent before inclusion in the study~Exclusion Criteria:~* Participants who are taking any antiretrovirals other than nucleoside/nucleotide reverse transcriptase inhibitors and LPV/r~* Any prior history of genotype-documented protease inhibitor resistance~* Participants who are taking rifampicin or any other therapy with major cytochrome P450 interactions, within the last month~* Participants who are allergic to sulphonamides~* Participants who have a current history of drug or alcohol abuse that, in the opinion of the investigator, may be an impediment to participant adherence to the protocol~* Female participants who are currently pregnant or breastfeeding~* Female participants desiring pregnancy during the next year~* Participants who have a strong likelihood of relocating far enough to make access to the study site difficult~* Any condition(s) or laboratory report that, in the opinion of the investigator, might put the participant at risk, or interfere with the study objectives or the participant's adherence to study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Darunavir (Type: ACTIVE_COMPARATOR): Darunavir/Ritonavir 400/100mg once daily
- Lopinavir (Type: ACTIVE_COMPARATOR): Lopinavir/Ritonavir 400/100mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).